SCHEMBL14218905

SCHEMBL14218905

COCC(=O)Oc1ccc(C(C)(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 6/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
LMNA P02545 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HSD17B10 Q99714 2/20 0.50
ALOX15 P16050 1/20 0.50
APEX1 P27695 1/20 0.50
MAPK1 P28482 1/20 0.50
RECQL P46063 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
RAB9A P51151 5/20 0.47
NPC1 O15118 3/20 0.47
HTT P42858 2/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.46
GAA P10253 1/20 0.46
EPHX2 P34913 1/20 0.44
NR1H4 Q96RI1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5696642 0.87 KMT2A (0.59) SMN1; SMN2MAPTL3MBTL1TDP1LMNA
SCHEMBL13298324 0.85 TDP1 (0.48) SMN1; SMN2MAPTTDP1LMNAALDH1A1
SCHEMBL1205813 0.83 MAPT (0.56) SMN1; SMN2MAPTL3MBTL1TDP1LMNA
SCHEMBL9765294 0.81 MAPT (0.54) SMN1; SMN2MAPTL3MBTL1TDP1LMNA
SCHEMBL120180 0.81 KMT2A (0.59) SMN1; SMN2MAPTL3MBTL1TDP1LMNA
SCHEMBL13290651 0.81 SMN1; SMN2 (0.50) SMN1; SMN2MAPTL3MBTL1TDP1LMNA
SCHEMBL18087017 0.81 LMNA (0.53) SMN1; SMN2MAPTL3MBTL1TDP1LMNA
SCHEMBL10625899 0.80 SMN1; SMN2 (0.66) SMN1; SMN2MAPTL3MBTL1TDP1LMNA
SCHEMBL13290630 0.80 MAPT (0.53) SMN1; SMN2MAPTL3MBTL1TDP1LMNA
SCHEMBL11704915 0.80 MAPT (0.53) SMN1; SMN2MAPTL3MBTL1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368563-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20070155675-A1 Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155675-A1 Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof APOB, NPC1L1, CYP46A1 SMN1; SMN2 207/4885MAPT 3636/4885L3MBTL1 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.